Brief: Oragenics Initiates Pivotal IND-Enabling Toxicology Study On Its Intranasal COVID-19 Vaccine Candidate
22/03/2022 13:42
March 22 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS INITIATES A PIVOTAL IND-ENABLING TOXICOLOGY
STUDY ON
ITS INTRANASAL COVID-19 VACCINE CANDIDATE, NT-COV2-1
* ORAGENICS INC - DATA TO ESTABLISH SAFETY PROFILE AND HUMAN
DOSE
OF VACCINE CANDIDATE
* ORAGENICS INC - HAS CONTRACTED WITH FRONTAGE LABORATORIES
TO
CONDUCT STUDY, WITH TOP-LINE INTERIM DATA EXPECTED IN AUGUST
Source text for Eikon: ID:nBw89p35Wa
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing